- Initiation of first clinical study of multivalent VBI-2901, designed to increase breadth of protection against COVID-19 and related coronaviruses
- Preclinical data support broadly reactive immunity of VBI-2901 against a panel of coronavirus variants in mice, which now also includes circulating BA.4 and BA.5
- The study is expected to enroll approximately 100 adults in Canada and is supported by the Government of Canada
- Interim data expected mid-year 2023, subject to speed of enrollment
VBI Vaccines Announces Initiation Of Phase 1 Study Of Multivalent Coronavirus Vaccine Candidate, VBI-2901
Initiation of first clinical study of multivalent VBI-2901, designed to increase breadth of protection against COVID-19 and related coronaviruses
Preclinical data support broadly reactive immunity of VBI-2901 against
